Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 12/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18257860 | 0.90 | ESR2 (0.82) | ESR2JAK2JAK1KDM4EALDH1A1 | |
| SCHEMBL1171537 | 0.87 | ESR2 (0.78) | ESR2JAK2JAK1KDM4EALDH1A1 | |
| SCHEMBL28123495 | 0.85 | ESR2 (0.74) | ESR2JAK2JAK1KDM4EALDH1A1 | |
| SCHEMBL382783 | 0.84 | ESR2 (0.72) | ESR2CA12CA1CA2CA7 | |
| SCHEMBL3302628 | 0.83 | ESR2 (0.71) | ESR2JAK2JAK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17730173 | 0.83 | ESR2 (0.69) | ESR2JAK2JAK1CA12CA1 | |
| SCHEMBL19853819 | 0.82 | ESR2 (0.70) | ESR2JAK2JAK1 | |
| SCHEMBL4335569 | 0.82 | ESR2 (0.69) | ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5534578 | 0.81 | ESR2 (0.67) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL13009589 | 0.80 | ESR2 (0.67) | ESR2JAK2JAK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3071541-B1 | SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOALKANE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM | UNIV MARQUETTE (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210340155-A1 | Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation | CU Ventures, Inc. | 2021-11-04 | — | — | US | disclosed |
| CN-106999450-B | Immunomodulator | 弗莱塞斯生物科学公司 | 2021-07-09 | — | — | CN | disclosed |
| US-10987322-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10987322-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3215142-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20150157611-A1 | COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE I ENZYME | KAINOS MEDICINE, INC. (KR) | 2015-06-11 | — | — | US | disclosed |
| US-20150157611-A1 | COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE I ENZYME | KAINOS MEDICINE, INC. (KR) | 2015-06-11 | — | — | US | disclosed |
| CN-104245696-A | Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | KAINOS MEDICINE INC | 2014-12-24 | — | — | CN | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| WO-2013119040-A1 | COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | KAINOS MEDICINE, INC. (KR) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013119040-A1 | COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | KAINOS MEDICINE, INC. (KR) | 2013-08-15 | — | — | WO | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| WO-2010086551-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242319-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | ESR2 1493/4885JAK2 1134/4885JAK1 1436/4885 |
| US-20210340155-A1 | Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation | ESR2, GPER1, ESR1 | ESR2 1/4885JAK2 3889/4885JAK1 4828/4885 |
| US-20150157611-A1 | COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE I ENZYME | DGAT1, DGAT2, SOAT1 | ESR2 2959/4885JAK2 4042/4885JAK1 3748/4885 |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | ESR2 4767/4885JAK2 148/4885JAK1 140/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | ESR2 1493/4885JAK2 1134/4885JAK1 1436/4885 |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | ESR2 1493/4885JAK2 1134/4885JAK1 1436/4885 |
| US-10987322-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | ESR2 1493/4885JAK2 1134/4885JAK1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.